Oncolytics Biotech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Oncolytics Biotech kazanç ve gelirinin sırasıyla yıllık 47.6% ve 51.6% oranında artması tahmin edilirken, EPS'nin yıllık 50.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

47.6%

Kazanç büyüme oranı

50.23%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.2%
Gelir büyüme oranı	51.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	05 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha

Analiz Makalesi • Sep 03

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Mar 11

Oncolytics Biotech: Continuing To Justify The Negativity

Summary Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in pancreatic cancer continues, but key data readouts are not expected until late 2025, adding uncertainty. ONCY's financial situation is dire, with cash runway only into Q3 2025, raising serious concerns about their ability to fund operations. Given the high risk, low market cap, and lack of clear efficacy, I maintain a "Sell" rating and advise against investing in ONCY. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ONCY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	14	-26	N/A	N/A	3
12/31/2027	N/A	-30	N/A	N/A	4
12/31/2026	N/A	-30	N/A	N/A	5
3/31/2026	N/A	-33	-23	-23	N/A
12/31/2025	N/A	-29	-20	-20	N/A
9/30/2025	N/A	-25	-19	-19	N/A
6/30/2025	N/A	-22	-18	-18	N/A
3/31/2025	N/A	-22	-18	-18	N/A
12/31/2024	N/A	-23	-20	-20	N/A
9/30/2024	N/A	-20	-19	-19	N/A
6/30/2024	N/A	-20	-19	-19	N/A
3/31/2024	N/A	-21	-21	-21	N/A
12/31/2023	N/A	-21	-21	-21	N/A
9/30/2023	N/A	-24	-21	-21	N/A
6/30/2023	N/A	-20	-20	-20	N/A
3/31/2023	N/A	-18	-18	-18	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	N/A	-17	-17	-17	N/A
6/30/2022	N/A	-19	-18	-18	N/A
3/31/2022	N/A	-21	-19	-18	N/A
12/31/2021	N/A	-21	-18	-18	N/A
9/30/2021	N/A	-22	-17	-17	N/A
6/30/2021	N/A	-24	-20	-20	N/A
3/31/2021	N/A	-23	-19	-19	N/A
12/31/2020	N/A	-18	-17	-17	N/A
9/30/2020	N/A	-24	-18	-18	N/A
6/30/2020	N/A	-22	-16	-16	N/A
3/31/2020	N/A	-20	-15	-15	N/A
12/31/2019	N/A	-26	N/A	-15	N/A
9/30/2019	N/A	-14	N/A	-13	N/A
6/30/2019	N/A	-14	N/A	-12	N/A
3/31/2019	N/A	-13	N/A	-8	N/A
12/31/2018	N/A	-12	N/A	-9	N/A
9/30/2018	N/A	-13	N/A	-8	N/A
6/30/2018	N/A	-13	N/A	-8	N/A
3/31/2018	N/A	-13	N/A	-12	N/A
12/31/2017	N/A	-12	N/A	-12	N/A
9/30/2017	N/A	-13	N/A	-12	N/A
6/30/2017	N/A	-13	N/A	-12	N/A
3/31/2017	N/A	-11	N/A	-10	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-10	N/A	-10	N/A
6/30/2016	N/A	-10	N/A	-10	N/A
3/31/2016	N/A	-11	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-11	N/A
9/30/2015	N/A	-10	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ONCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ONCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ONCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ONCY gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: ONCY gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ONCY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/17 22:53
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Oncolytics Biotech Inc. 19 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Douglas Loe	Cantor Fitzgerald Canada Corporation
Wang Chong	Edison Investment Research
Patrick Trucchio	H.C. Wainwright & Co.

Oncolytics Biotech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2027

Forecast to breakeven in 2026

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

New minor risk - Market cap size

Oncolytics Biotech Reports 33% Response Rate With Pelareorep in Advanced Colorectal Cancer

Oncolytics Biotech Inc. Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech Inc Aligns with Fda on Planned Pivotal Anal Cancer Study

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Oncolytics Biotech Inc Schedules Type C FDA Meeting to Discuss Single-Arm Registrational Pathway for Pelareorep in Anal Cancer

New major risk - Shareholder dilution

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Market cap size

Oncolytics Biotech Inc. Presents New Mechanistic And Translational Data Supporting Pelareorep as An Immune-Priming Backbone

Oncolytics Biotech Launches Randomized Colorectal Cancer Study

Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Independent Director recently bought US$83k worth of stock

New minor risk - Market cap size

Oncolytics Biotech®? Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

New minor risk - Share price stability

Independent Director recently bought US$104k worth of stock

Oncolytics Biotech Inc. Appoints Yujun Wu as Vice President, Head of Biostatistics

Oncolytics Biotech Announces Updated Clinical Data from GOBlet Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings

Oncolytics Biotech Inc. Expands Scientific Advisory Board with the Appointment of Eileen O’Reilly, Neil Segal, and Van Morris

Oncolytics Biotech Inc. Announces Promising Efficacy and Translational Data Supporting Pelareorep in Kras-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

New minor risk - Profitability

Oncolytics Biotech Inc. Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More than Double the Current Standard of Care

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech®? Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

New minor risk - Profitability

New major risk - Shareholder dilution

New major risk - Financial position

Oncolytics Biotech Inc. to Report Q2, 2025 Results on Aug 08, 2025

Oncolytics Biotech Inc. Begins Formal Discussions with the U.S. Food and Drug Administration Aimed at Finalizing A Pivotal Study Design

CEO & Director recently bought US$60k worth of stock

Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech Inc. Appoints Andrew Aromando as Chief Business Officer

Oncolytics Biotech Inc. Appoints Jared Kelly as Chief Executive Officer

New minor risk - Share price stability

Oncolytics Biotech Inc., Annual General Meeting, Aug 08, 2025

New minor risk - Shareholder dilution

Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Oncolytics Biotech: Continuing To Justify The Negativity

New minor risk - Profitability

New minor risk - Share price stability

Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Matt Coffey Steps Down as Chief Executive Officer of Oncolytics Biotech Inc

Forecast to breakeven in 2027

Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium

Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort

New major risk - Financial position

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

New minor risk - Share price stability

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.